Skip to main content
SpringerLink
Log in

RAS-Blocker und Diabetes: Wackelt das Dogma?

  • Literatur kompakt
  • Published:
CardioVasc Aims and scope

Die Präferenz für RAS-Blocker bei Hypertonie und Diabetes mellitus ist ein seit Langem geübter und kaum infrage gestellter Brauch. Die vorliegende Metaanalyse kommt zu überraschenden Ergebnissen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  • Bangalore S et al. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016;352:i438

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik IV, Charité Universitätsmedizin Berlin, Berlin, Deutschland

    Walter Zidek

Authors
  1. Walter Zidek
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zidek, W. RAS-Blocker und Diabetes: Wackelt das Dogma?. CV 16, 65–66 (2016). https://doi.org/10.1007/s15027-016-0878-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-016-0878-y

Search

Navigation